Avidity Biosciences saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 74 to 81.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Avidity Biosciences is not currently showing a potential buy point. See if the stock goes on to form a base that could kick off a new climb.
Avidity Biosciences posted 0% EPS growth in the latest quarterly report. Revenue increased -17%.
Avidity Biosciences earns the No. 264 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
